Purpose: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements
in survival seen following currently available salvage therapy. This study was conducted to …

Purpose To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca,
Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients …

Loss of PTEN tumor suppressor function is observed in tumors of breast, prostate, thyroid,
and endometrial origin. Allelic losses in the proximity of the PTEN locus (10q23) also occur in …

Purpose We performed a phase II study to evaluate the combination of imatinib mesylate,
an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a …

Colorectal cancer (CRC) can progress through two pathways of genomic instability:
chromosomal (CIN) and microsatellite instability (MSI). We hypothesized that these two pathways …

Purpose: More brain tumor markers are required for prognosis and targeted therapy. We
have identified and validated promising molecular therapeutic glioblastoma multiforme (GBM) …

Purpose Allogeneic transplantation is typically limited to younger patients having a matched
donor. To allow a donor to be found for nearly all patients, we have used a …

Purpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT)
of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …

Runt domain transcription factors are important targets of TGF‐β superfamily proteins and play
a crucial role in mammalian development. Three mammalian runt‐related genes, RUNX1, …

BACKGROUND. Significant barriers to cancer patients receiving mental health treatment for
distress have been reported in the literature. The objective of the current study was to …